LAB 📈 Standard Biotools - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US34385P1084
LAB: Analytical Systems, Genomics Instruments, Reagents, Software, Consumables
Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California. Web URL: https://www.standardbio.com
Additional Sources for LAB Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
LAB Stock Overview
Market Cap in USD | 797m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception | 2003-07-29 |
LAB Stock Ratings
Growth 5y | -51.9% |
Fundamental | -50.7% |
Dividend | - |
Rel. Strength Industry | -29.5 |
Analysts | 5/5 |
Fair Price Momentum | 1.65 USD |
Fair Price DCF | - |
LAB Dividends
No Dividends PaidLAB Growth Ratios
Growth Correlation 3m | 13.5% |
Growth Correlation 12m | -65.1% |
Growth Correlation 5y | -63.9% |
CAGR 5y | -10.05% |
CAGR/Mean DD 5y | -0.16 |
Sharpe Ratio 12m | 0.36 |
Alpha | -49.92 |
Beta | 2.14 |
Volatility | 102.03% |
Current Volume | 4657.1k |
Average Volume 20d | 1603.8k |
What is the price of LAB stocks?
As of December 21, 2024, the stock is trading at USD 2.00 with a total of 4,657,077 shares traded.
Over the past week, the price has changed by +4.71%, over one month by +24.22%, over three months by -0.50% and over the past year by +3.63%.
As of December 21, 2024, the stock is trading at USD 2.00 with a total of 4,657,077 shares traded.
Over the past week, the price has changed by +4.71%, over one month by +24.22%, over three months by -0.50% and over the past year by +3.63%.
Is Standard Biotools a good stock to buy?
No, based on ValueRay Fundamental Analyses, Standard Biotools (NASDAQ:LAB) is currently (December 2024) a stock to sell. It has a ValueRay Fundamental Rating of -50.74 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LAB as of December 2024 is 1.65. This means that LAB is currently overvalued and has a potential downside of -17.5%.
No, based on ValueRay Fundamental Analyses, Standard Biotools (NASDAQ:LAB) is currently (December 2024) a stock to sell. It has a ValueRay Fundamental Rating of -50.74 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LAB as of December 2024 is 1.65. This means that LAB is currently overvalued and has a potential downside of -17.5%.
Is LAB a buy, sell or hold?
Standard Biotools has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy LAB.
Standard Biotools has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy LAB.
- Strong Buy: 3
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for LAB stock price target?
According to ValueRays Forecast Model, LAB Standard Biotools will be worth about 1.9 in December 2025. The stock is currently trading at 2.00. This means that the stock has a potential downside of -5.5%.
According to ValueRays Forecast Model, LAB Standard Biotools will be worth about 1.9 in December 2025. The stock is currently trading at 2.00. This means that the stock has a potential downside of -5.5%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 3.1 | 54% |
Analysts Target Price | 0.6 | -72.5% |
ValueRay Target Price | 1.9 | -5.5% |